Evidence map›Paper›PMID 42772903›Full record

ArticleLife science alliance2026

RAF1 scaffold integrity shapes chemogenetic degradation outcomes in KRAS-driven lung cancer models.

Laura de-la-Puente-Ovejero, Ana Domostegui, Inés María García-Pérez, Gonzalo Aizpurua, Lucía Lomba-Riego, Pilar Ximenez-Embún, Cristina Mayor-Ruiz, Mariano Barbacid, Sara García-Alonso

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Life science alliance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Laura de-la-Puente-OvejeroExperimental Oncology Group, Tumor Biology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.
Ana DomosteguiInstitute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain.
Inés María García-PérezInstitute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain.
Gonzalo AizpuruaExperimental Oncology Group, Tumor Biology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.
Lucía Lomba-RiegoExperimental Oncology Group, Tumor Biology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.
Pilar Ximenez-EmbúnProteomics Unit, Biotechnology Program, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.
Cristina Mayor-RuizInstitute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain.
Mariano BarbacidExperimental Oncology Group, Tumor Biology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain mbarbacid@cnio.es.ORCID https://orcid.org/0000-0002-1480-2624
Sara García-AlonsoExperimental Oncology Group, Tumor Biology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain sgarciaa@cnio.es.ORCID https://orcid.org/0000-0002-0561-4146

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Scaffold integrity is essential for the activity of proteins that function through protein-protein interactions rather than catalytic output. RAF1 exemplifies this duality: although it is a bona fide kinase and a core component of the MAPK cascade, its tumor-promoting role is largely kinase-independent, relying instead on scaffold-mediated suppression of apoptosis. Genetic

Indexed as

Lung NeoplasmsProto-Oncogene Proteins c-rafProto-Oncogene Proteins p21(ras)AnimalsApoptosisChemogeneticsDisease Models, AnimalHumansMiceProteolysisHras protein, mouseProto-Oncogene Proteins c-rafProto-Oncogene Proteins p21(ras)Raf1 protein, humanRaf1 protein, mouse

Identifiers

PMID42772903
PMCPMC13598765

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.